Krystal Biotech, Inc., the leader in redosable gene therapy, announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14.
PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14.
Krish Krishnan, Chairman and Chief Executive Officer, will deliver a presentation and host investor meetings on September 13.
A webcast of the presentation will be available here beginning at 2:30pm ET on Tuesday, September 13 and will be posted on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACT:
Investors and Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Source: Krystal Biotech, Inc.
